Titan Pharmaceuticals Statistics
Total Valuation
TTNP has a market cap or net worth of $3.15 million. The enterprise value is -$427,740.
Important Dates
The next estimated earnings date is Monday, March 31, 2025, after market close.
| Earnings Date | Mar 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TTNP has 914,234 shares outstanding. The number of shares has increased by 15.09% in one year.
| Current Share Class | 914,234 |
| Shares Outstanding | 914,234 |
| Shares Change (YoY) | +15.09% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 23.43% |
| Owned by Institutions (%) | 2.83% |
| Float | 700,056 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.92 |
| P/TBV Ratio | 0.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.71
| Current Ratio | 9.71 |
| Quick Ratio | 9.30 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -485.17 |
Financial Efficiency
Return on equity (ROE) is -103.59% and return on invested capital (ROIC) is -60.84%.
| Return on Equity (ROE) | -103.59% |
| Return on Assets (ROA) | -53.51% |
| Return on Invested Capital (ROIC) | -60.84% |
| Return on Capital Employed (ROCE) | -180.19% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.47M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.61% in the last 52 weeks. The beta is 1.14, so TTNP's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | -49.61% |
| 50-Day Moving Average | 3.50 |
| 200-Day Moving Average | 5.18 |
| Relative Strength Index (RSI) | 45.61 |
| Average Volume (20 Days) | 36,949 |
Short Selling Information
The latest short interest is 14,785, so 1.62% of the outstanding shares have been sold short.
| Short Interest | 14,785 |
| Short Previous Month | 12,836 |
| Short % of Shares Out | 1.62% |
| Short % of Float | 2.11% |
| Short Ratio (days to cover) | 1.04 |
Income Statement
| Revenue | n/a |
| Gross Profit | -487,000 |
| Operating Income | -5.82M |
| Pretax Income | -4.95M |
| Net Income | -5.89M |
| EBITDA | -5.81M |
| EBIT | -5.82M |
| Earnings Per Share (EPS) | -$6.85 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 3.40M |
| Total Debt | n/a |
| Net Cash | 3.40M |
| Net Cash Per Share | $3.72 |
| Equity (Book Value) | 3.23M |
| Book Value Per Share | 3.53 |
| Working Capital | 3.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.62 million and capital expenditures -$2,000, giving a free cash flow of -$5.62 million.
| Operating Cash Flow | -5.62M |
| Capital Expenditures | -2,000 |
| Free Cash Flow | -5.62M |
| FCF Per Share | -$6.15 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |